Prostate Cancer Managed with Active Surveillance: Role of Anatomic MR Imaging and MR Spectroscopic Imaging

被引:101
|
作者
Fradet, Vincent [2 ]
Kurhanewicz, John [1 ]
Cowan, Janet E. [2 ]
Karl, Alexander [2 ]
Coakley, Fergus V. [2 ]
Shinohara, Katsuto [2 ]
Carroll, Peter R. [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Urol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
基金
美国国家卫生研究院;
关键词
ENDORECTAL MR; INCREMENTAL VALUE; TUMOR; MEN; PREDICTION; ANTIGEN; LOCALIZATION; SUPPRESSION; BIOPSY; MARKER;
D O I
10.1148/radiol.10091147
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine the role that magnetic resonance (MR) imaging and MR spectroscopic imaging findings obtained at the time of diagnosis play in the progression of disease in patients whose prostate cancer is being managed with active surveillance and to compare the role of these findings with the role of transrectal ultrasonography (US) findings. Materials and Methods: The institutional review board approved this HIPAA-compliant retrospective study, and informed consent was obtained from all patients whose records were to be entered into the research database. All patients who had prostate cancer managed with active surveillance and who had undergone both MR imaging and MR spectroscopic imaging of the prostate and transrectal US at time of diagnosis were identified. Two urologists blinded to the clinical outcome in these patients independently reviewed and dichotomized the MR imaging report and the MR spectroscopic imaging report as normal or suggestive of malignancy. One experienced urologist performed all US examinations that were then dichotomized similarly. Uni- and multivariate (with use of standard clinical variables) Cox models were fitted to assess time to cancer progression, defined as Gleason score upgrading, prostate-specific antigen velocity of more than 0.75 (mu g . L-1)/y, or initiation of treatment more than 6 months after diagnosis. Results: The final cohort included 114 patients with a median follow-up of 59 months. Patients with a lesion that was suggestive of cancer at MR imaging had a greater risk of the Gleason score being upgraded at subsequent biopsy (hazard ratio, 4.0; 95% confidence interval: 1.1, 14.9) than did patients without such a lesion. Neither MR spectroscopic imaging nor transrectal US could be used to predict cancer progression. Conclusion: Abnormal prostate MR imaging results suggestive of cancer may confer an increased risk of Gleason score upgrade at subsequent biopsy. Although expensive, prostate MR imaging may help in counseling potential candidates about active surveillance. (C) RSNA, 2010
引用
收藏
页码:176 / 183
页数:8
相关论文
共 50 条
  • [21] MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer (Publication with Expression of Concern)
    Hricak, H
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2005, 78 : S103 - S111
  • [22] Localization of prostate cancer by endorectal MR imaging and MR spectroscopic imaging: Effect of clinical data on reader accuracy
    Dhingsa, R
    Coakley, FV
    Qayyum, A
    Kurhanewicz, J
    Yeh, BM
    Carroll, PR
    [J]. RADIOLOGY, 2002, 225 : 629 - 629
  • [23] Future role of ultrasound and MR imaging in prostate cancer
    Bloch, B. Nicolas
    Kuligowska, Ewa
    [J]. JOURNAL OF ULTRASONOGRAPHY, 2015, 15 (60) : 102 - 104
  • [24] SERIAL ANATOMIC PROSTATE ULTRASOUND IMAGING DURING PROSTATE CANCER ACTIVE SURVEILLANCE
    Eltemamy, Mohamed
    Leapman, Michael
    Cowan, Janet
    Shinohara, Katsuto
    Westphalen, Antonio
    Carroll, Peter
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E154 - E154
  • [25] MR imaging and MR spectroscopy in prostate cancer management
    Katz, Sharyn
    Rosen, Mark
    [J]. RADIOLOGIC CLINICS OF NORTH AMERICA, 2006, 44 (05) : 723 - +
  • [26] MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores
    Nagarajan, Rajakumar
    Margolis, Daniel
    Raman, Steven
    Sarma, Manoj K.
    Sheng, Ke
    King, Christopher R.
    Verma, Gaurav
    Sayre, James
    Reiter, Robert E.
    Thomas, M. Albert
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2012, 36 (03) : 697 - 703
  • [27] Clinical Stage T1c Prostate Cancer: Evaluation with Endorectal MR Imaging and MR Spectroscopic Imaging
    Zhang, Jingbo
    Hricak, Hedvig
    Shukla-Dave, Amita
    Akin, Oguz
    Ishill, Nicole M.
    Carlino, Lauren J.
    Reuter, Victor E.
    Eastham, James A.
    [J]. RADIOLOGY, 2009, 253 (02) : 425 - 434
  • [28] Prostate cancer: Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging
    Yu, KK
    Scheidler, J
    Hricak, H
    Vigneron, DB
    Zaloudek, CJ
    Males, RG
    Nelson, SJ
    Carroll, PR
    Kurhanewicz, J
    [J]. RADIOLOGY, 1999, 213 (02) : 481 - 488
  • [29] Detection of prostate cancer: Utility of diffusion-weighted MR imaging and 3D MR spectroscopic imaging
    Gouhar, Ghada K.
    Taha, Tamer F.
    Allam, Mohamed N.
    [J]. EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE, 2010, 41 (03): : 429 - 439
  • [30] Prediction of organ-confined prostate cancer: Incremental value of MR imaging and MR spectroscopic imaging to staging nomograms
    Wang, L
    Hricak, H
    Kattan, MW
    Chen, HN
    Scardino, PT
    Kuroiwa, K
    [J]. RADIOLOGY, 2006, 238 (02) : 597 - 603